Article
Oncology
Barbara Rath, Adelina Plangger, Dagmar Krenbek, Maximilian Hochmair, Sandra Stickler, Verena Tretter, Gerhard Hamilton
Summary: This study tested the anti-tumor activity of the anti-DLL3 drug conjugate ROVA-T against SCLC and identified a link between resistance to ROVA-T and DLL3 expression as well as cell growth morphology.
Article
Oncology
Daniel J. Lindner, Gary Wildey, Yvonne Parker, Afshin Dowlati, George R. Stark, De Sarmishtha
Summary: The study investigated the potential effect of combining Rova-T and CBL in small cell lung cancer to eradicate tumor-initiating cells more effectively, presenting a novel therapeutic strategy for increasing survival rates in SCLC patients.
BRITISH JOURNAL OF CANCER
(2021)
Article
Oncology
Aaron S. Mansfield, David S. Hong, Christine L. Hann, Anna F. Farago, Himisha Beltran, Saiama N. Waqar, Andrew E. Hendifar, Lowell B. Anthony, Matthew H. Taylor, Alan H. Bryce, Scott T. Tagawa, Karl Lewis, Jiaxin Niu, Christine H. Chung, James M. Cleary, Michael Rossi, Carrianne Ludwig, Ricardo Valenzuela, Yan Luo, Rahul Aggarwal
Summary: Rova-T at 0.3 mg/kg q6w showed manageable toxicity with antitumor activity observed in patients with NEC/NET, melanoma, MTC, and glioblastoma.
NPJ PRECISION ONCOLOGY
(2021)
Article
Medicine, General & Internal
Snehasis Das, Sagar Prakash, Oseen Shaikh, Abhinaya Reddy, Uday Kumbhar
Summary: Primary neuroendocrine carcinoma of the gallbladder is a rare and highly lethal disease. A 45-year-old female presented with symptoms of abdominal pain and vomiting. Imaging studies revealed extensive spread of the cancer to nearby structures and lymph nodes. The patient underwent a fine-needle aspiration, which confirmed the diagnosis of small cell carcinoma of the gallbladder. Palliative chemotherapy was planned as the treatment option.
CUREUS JOURNAL OF MEDICAL SCIENCE
(2023)
Article
Chemistry, Multidisciplinary
Yoon-Tae Kang, Zeqi Niu, Thomas Hadlock, Emma Purcell, Ting-Wen Lo, Mina Zeinali, Sarah Owen, Venkateshwar G. Keshamouni, Rishindra Reddy, Nithya Ramnath, Sunitha Nagrath
Summary: NK cells and their derived exosomes play a crucial role in cancer immunotherapy, as they exhibit high stability and lower immunogenicity, providing possibilities for personalized treatments. A novel microfluidic system for collecting patient-specific NK cells and NK-exosomes on chips offers potential applications in cancer therapies.
Article
Medicine, General & Internal
Abbas Eshraghi, Mohammad Mehdi Riyahi, Afshin Ghaderi, Maedeh Alsadat Fatemi, Azhar Eshraghi, Danial Fazilat-Panah
Summary: This is a case report of small cell carcinoma of the bladder with extensive lymph node metastases, who underwent radical cystoprostatectomy followed by adjuvant systemic chemotherapy and chemoradiotherapy.
CLINICAL CASE REPORTS
(2022)
Article
Medicine, General & Internal
Snehasis Das, Naveen Kumar Gaur, Oseen Shaikh, Gopal Balasubramanian, Sreerekha Jinkala
Summary: Primary small cell carcinoma of the esophagus is a rare and highly aggressive disease with a poor prognosis. The usual treatment is palliative chemoradiotherapy, as the disease is often metastatic. The prognosis is usually poor due to late-stage diagnosis.
CUREUS JOURNAL OF MEDICAL SCIENCE
(2021)
Article
Oncology
Masayuki Shirasawa, Tatsuya Yoshida, Kouya Shiraishi, Naoko Goto, Shigehiro Yagishita, Tatsuya Imabayashi, Yuji Matsumoto, Ken Masuda, Yuki Shinno, Yusuke Okuma, Yasushi Goto, Hidehito Horinouchi, Masaya Yotsukura, Yukihiro Yoshida, Kazuo Nakagawa, Katsuhiko Naoki, Takaaki Tsuchida, Ryuji Hamamoto, Noboru Yamamoto, Noriko Motoi, Takashi Kohno, Shun-ichi Watanabe, Yuichiro Ohe
Summary: In small-cell lung cancer patients, high expression of DLL3 is associated with a higher load of new antigens, but inhibits tumor immunity, making tumors resistant to immunochemotherapy.
BRITISH JOURNAL OF CANCER
(2023)
Article
Oncology
Wolf R. Wiedemeyer, Julia Gavrilyuk, Alexander Schammel, Xi Zhao, Hetal Sarvaiya, Marybeth Pysz, Christine Gu, Monica You, Kumiko Isse, Theodore Sullivan, Dorothy French, Christina Lee, Angeline T. Dang, Zhaomei Zhang, Monette Aujay, Alexander J. Bankovich, Philip Vitorino
Summary: In the past year, the number of approved antibody-drug conjugates (ADCs) in oncology has almost doubled, with four new ADCs being approved. Successful ADCs optimize various factors, such as targeting antibody, conjugation chemistry, and payload mechanism of action. This article describes the development of ABBV-011, a novel ADC that targets SEZ6 and uses calicheamicin as the payload for treating small cell lung cancer (SCLC). By engineering a calicheamicin conjugate without the acid-labile hydrazine linker, the release of toxic catabolite is avoided. Patient-derived xenograft screening identified SCLC as a tumor type with enhanced sensitivity to calicheamicin ADCs. ABBV-011, which targets SEZ6 and is rapidly internalized upon receptor binding, showed potent tumor regression in vitro and in vivo, suggesting it may provide a new treatment for SCLC patients.
MOLECULAR CANCER THERAPEUTICS
(2022)
Article
Health Care Sciences & Services
Eva Obermayr, Nina Koppensteiner, Nicole Heinzl, Eva Schuster, Barbara Holzer, Hannah Fabikan, Christoph Weinlinger, Oliver Illini, Maximilian Hochmair, Robert Zeillinger
Summary: This study highlighted the importance of molecular characterization of circulating tumor cells (CTCs) in NSCLC patients. The analysis found that cancer stem cell-related transcripts were significantly associated with overall survival at both primary diagnosis and disease progression.
JOURNAL OF PERSONALIZED MEDICINE
(2021)
Article
Biotechnology & Applied Microbiology
Wang Xinli, Wang Lixiao, Ding Baoqi, Huang Hu, Zhang Qiang
Summary: The expression of SOX11 differs significantly in different histological types of lung tumors, being highly expressed in SCLC. SOX11 can serve as a useful supplement to classical neuroendocrine markers and in combination with other markers for the diagnosis of SCLC.
BIOMED RESEARCH INTERNATIONAL
(2022)
Article
Oncology
Katharina Kriegsmann, Christiane Zgorzelski, Thomas Muley, Petros Christopoulos, Michael Thomas, Hauke Winter, Martin Eichhorn, Florian Eichhorn, Moritz von Winterfeld, Esther Herpel, Benjamin Goeppert, Albrecht Stenzinger, Felix J. F. Herth, Arne Warth, Mark Kriegsmann
Summary: A study of 1170 cases found that neuroendocrine markers synaptophysin, chromogranin, and CD56 are commonly expressed in pulmonary adenocarcinoma and squamous cell carcinoma, but their expression does not impact survival outcomes, aligning with current best practice guidelines.
Article
Oncology
Shunxing Teh, Fam Xeng Inn, Iqbal Hussain Rizuana, Wan Muhaizan Wm
Summary: This article presents a case of rare and highly aggressive small cell prostate neuroendocrine carcinoma. The case describes the patient's clinical presentation, imaging findings, and treatment plan. Consensus on the management of this disease is still lacking.
FRONTIERS IN ONCOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Woo Kyung Ryu, Sekyung Oh, Jun Hyeok Lim, Seung Jae Lee, Hyun-Tae Shin, Jeong-Seon Ryu
Summary: Recent research suggests that changes in ctDNA levels are correlated with TB changes, and the detection of ctDNA can be used to predict new metastases, rapid tumor growth, and poor survival in NSCLC patients.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Pathology
Keigo Murakami, Hiroyuki Kumata, Shigehito Miyagi, Takashi Kamei, Hironobu Sasano
Summary: In patients with hepatocellular carcinoma (HCC), the expression of synaptophysin can be used to predict an unfavorable prognosis, and is associated with other adverse clinicopathological factors.
PATHOLOGY INTERNATIONAL
(2021)
Article
Oncology
Konstantina Panoutsopoulou, Margaritis Avgeris, Konstantinos Mavridis, Tobias Dreyer, Julia Dorn, Eva Obermayr, Alexander Reinthaller, Kleita Michaelidou, Sven Mahner, Ignace Vergote, Adriaan Vanderstichele, Ioana Braicu, Jalid Sehouli, Robert Zeillinger, Viktor Magdolen, Andreas Scorilas
Article
Oncology
Rafal Watrowski, Dan Cacsire Castillo-Tong, Eva Obermayr, Robert Zeillinger
ANTICANCER RESEARCH
(2020)
Article
Oncology
Konstantina Panoutsopoulou, Margaritis Avgeris, Paraskevi Magkou, Konstantinos Mavridis, Tobias Dreyer, Julia Dorn, Eva Obermayr, Alexander Reinthaller, Kleita Michaelidou, Sven Mahner, Ignace Vergote, Liselore Loverix, Ioana Braicu, Jalid Sehouli, Robert Zeillinger, Viktor Magdolen, Andreas Scorilas
INTERNATIONAL JOURNAL OF CANCER
(2020)
Article
Oncology
Sabine Kasimir-Bauer, Joanna Roder, Eva Obermayr, Sven Mahner, Ignace Vergote, Liselore Loverix, Elena Braicu, Jalid Sehouli, Nicole Concin, Rainer Kimmig, Lelia Net, Heinrich Roder, Robert Zeillinger, Stefanie Aust
Article
Oncology
A. Hasenburg, D. Eichkorn, F. Vosshagen, E. Obermayr, A. Geroldinger, R. Zeillinger, M. Bossart
Summary: The study confirmed the accuracy of plasma CA125 as a tumor marker in ovarian cancer. By developing a formula combining CA125, HE4, OPN, leptin, and prolactin, successful prediction of malignant ovarian tumors was achieved. This formula showed high sensitivity and specificity in diagnosing malignant ovarian tumors.
Article
Oncology
Eva Obermayr, Angelika Reiner, Burkhard Brandt, Elena Ioana Braicu, Alexander Reinthaller, Liselore Loverix, Nicole Concin, Linn Woelber, Sven Mahner, Jalid Sehouli, Ignace Vergote, Robert Zeillinger
Summary: This study highlights the importance of a multifactorial approach to circulating tumor cells (CTCs) in ovarian cancer patients, in predicting survival rates and recurrence risks. Combining qPCR and IF methods can better capture the molecular phenotype shifts of CTCs and patients' treatment responses.
Article
Oncology
Konstantina Panoutsopoulou, Tobias Dreyer, Julia Dorn, Eva Obermayr, Sven Mahner, Toon van Gorp, Ioana Braicu, Robert Zeillinger, Viktor Magdolen, Margaritis Avgeris, Andreas Scorilas
Summary: This study evaluated the prognostic significance of tRNA-derived fragments (tRFs) in ovarian carcinomas for the first time. The results showed that i-tRF-GlyGCC was a novel molecular predictor of EOC prognosis, associated with a more aggressive phenotype and poor survival outcomes. The integration of i-tRF-GlyGCC with established prognostic markers improved patient risk stratification and clinical benefit in EOC prognosis.
Article
Oncology
Victoria Tserpeli, Dimitra Stergiopoulou, Dora Londra, Lydia Giannopoulou, Paul Buderath, Ioanna Balgkouranidou, Nikolaos Xenidis, Christina Grech, Eva Obermayr, Robert Zeillinger, Kitty Pavlakis, Theodoros Rampias, Stylianos Kakolyris, Sabine Kasimir-Bauer, Evi S. Lianidou
Summary: The study showed a significant correlation between DNA methylation of SLFN11 in plasma cfDNA and worse progression-free survival (PFS) in advanced stage HGSOC, indicating that this epigenetic alteration could be a predictor of resistance to platinum drugs in ovarian cancer. Further validation in larger patient cohorts is needed to explore the potential of SLFN11 promoter methylation as a prognostic biomarker and predictor of resistance to platinum-based chemotherapy in ovarian cancer.
Article
Oncology
Eva Obermayr, Elena Ioana Braicu, Stephan Polterauer, Liselore Loverix, Nicole Concin, Linn Woelber, Sven Mahner, Jalid Sehouli, Toon Van Gorp, Ignace Vergote, Robert Zeillinger, Stefanie Aust
Summary: This study explored the relationship between systemic markers of inflammation and the presence of circulating tumor cells in epithelial ovarian cancer patients. The findings suggest that a combined score for cancer exhaustion, integrating albumin and tryptophan metabolites, could serve as a prognostic biomarker for EOC. Additionally, the presence of CTCs was associated with this score, emphasizing the importance of systemic microenvironment in liquid biopsy biomarker assessment.
Article
Health Care Sciences & Services
Eva Obermayr, Nina Koppensteiner, Nicole Heinzl, Eva Schuster, Barbara Holzer, Hannah Fabikan, Christoph Weinlinger, Oliver Illini, Maximilian Hochmair, Robert Zeillinger
Summary: This study highlighted the importance of molecular characterization of circulating tumor cells (CTCs) in NSCLC patients. The analysis found that cancer stem cell-related transcripts were significantly associated with overall survival at both primary diagnosis and disease progression.
JOURNAL OF PERSONALIZED MEDICINE
(2021)
Article
Oncology
Rafal Watrowski, Eva Obermayr, Christine Wallisch, Stefanie Aust, Nicole Concin, Elena Ioana Braicu, Toon Van Gorp, Annette Hasenburg, Jalid Sehouli, Ignace Vergote, Robert Zeillinger
Summary: In this study, new proteomic-based models for non-invasive diagnosis of ovarian cancer (OC) were developed and validated. These models showed excellent performance in postmenopausal women but performed poorly in premenopausal patients and those with normal CA125 levels. Comparison with other algorithms and markers revealed no clear superiority of any model.
Article
Oncology
Constantin Sajdik, Eva Schuster, Barbara Holzer, Michael Krainer, Christine Deutschmann, Stefan Peter, Maximilian Marhold, Robert Zeillinger, Eva Obermayr
Summary: The analysis of circulating tumor cells (CTCs) is a technical challenge, and this study compares different microfluidic enrichment protocols for isolating these rare cells. The gene expression levels of CTC-related transcripts were analyzed using quantitative real-time PCR.
BREAST CANCER RESEARCH AND TREATMENT
(2022)
Article
Medical Laboratory Technology
Eva Obermayr, Nina Koppensteiner, Nicole Heinzl, Eva Schuster, Barbara Holzer, Hannah Fabikan, Christoph Weinlinger, Oliver Illini, Maximilian J. Hochmair, Robert Zeillinger
Summary: This study assessed the stability of CTC-related transcripts during storage and found that some genes were unaffected or upregulated upon storage, still associated with poor prognosis, while others were no longer associated with overall survival. These findings highlight the surprising stability of CTC-related transcripts.
CLINICAL CHEMISTRY AND LABORATORY MEDICINE
(2023)
Article
Oncology
Eva Welsch, Eva Schuster, Michael Krainer, Maximilian Marhold, Rupert Bartsch, Michael B. Fischer, Michael Hermann, Gabriele Hastermann, Heidemarie Uher, Gerhard Sliutz, Birgit Anker, Robert Zeillinger, Eva Obermayr
Summary: Liquid biopsy is a promising tool for monitoring cancer therapy, but further research is needed to improve sensitivity, specificity, standardization, and cost-effectiveness. In this study, two panels of transcripts related to circulating tumor cells (CTCs) were evaluated in breast cancer patients. The positivity rates of these panels were higher in metastatic patients compared to early-stage patients. Certain individual markers within these panels correlated with shorter overall survival in the metastatic patients. The findings highlight the additional value of non-epithelial phenotype markers in Panel 2.
Meeting Abstract
Oncology
P. Speiser, E. Maritschnegg, F. Heitz, N. Pecha, J. Bouda, F. Trillsch, C. Grimm, A. Vanderstichele, C. Agreiter, P. Harter, E. Obermayr, I. Vergote, R. Zeillinger, J. J. Salk, R. A. Risques
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
(2019)